Objective: To investigate the regulatory effect on nuclear factor-κB(NF-κB) signaling pathways of Shenxin Maihe particles based on treating coronary heart disease (CHD) in ischemia-reper fusion injury model rats. Method: Sixty SD rats were randomly divided into the sham operation group

the model group

the diltiazem group (36 mg·kg-1)

the low-

moderate- and high-dose Shenxin Maihe particles groups (0.17

0.51

1.53 g·kg-1). All rats received the corresponding medicines by intragastric adiminstration once daily for 7 days. Contents of interleukin (IL) -6 and IL-8 in the rats serum were detected by ELISA

the mRNA expressions of NF-κB

tumor necrosis factor-α(TNF-α)

inducible nitric oxide synthase (iNOS)

intercellular surface adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecules-1 (VCAM-1) in the tissue of rats were detected by RT-PCR

the protein expressions of vascular endothelial growth factor (VEGF)

heat shock protein 70 (HSP 70) and cyclooxygenase-2 (COX-2) were detected by Western blotting. Result: Compared with the sham operation group

the levels of IL-6 and IL-8 increased

the mRNA expressions of NF-κB

TNF-α

iNOS

ICAM-1 and VCAM-1 increased

the protein expression of COX-2 increased

the protein expressions of VEGF and HSP 70 decreased in the model group (P<0.01). Compared to the model group

Shenxin Maihe particles could improve the above indicators significantly (P<0.01). Conclusion: Shenxin Maihe particles has an evident effect against myocardial ischemia injury. Its mechanism may be related to the inhibition of inflammatory cytokines in the NF-κB signaling pathways and activating blood vessel protection factor synergistically. The results provide relevant theory basis for popularization and application of Shenxin Maihe particles in treating CHD.